PatentsDB

Genome Engineering

US2016369301A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016369301-A1
Application numberUS-201414907605-A
CountryUS
Kind codeA1
Filing dateJul 25, 2014
Priority dateJul 26, 2013
Publication dateDec 22, 2016
Grant date—

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods of genome engineering in cells using a TALEN lacking repeat sequences or Cas9 is provided.

First claim

Opening claim text (preview).

What is claimed is: 1 . A method of altering target DNA in a cell comprising introducing into a cell a TALEN lacking repeat sequences 100 bp or longer wherein the TALEN cleaves the target DNA and the cell undergoes nonhomologous end joining to produce altered DNA in the cell. 2 - 5 . (canceled) 6 . The method of claim 1 wherein the TALEN lacks repeat sequences 50 bp or longer. 7 - 18 . (canceled) 19 . The method of claim 1 wherein the TALEN lacks repeat sequences 10 bp or longer. 20 . The method of claim 1 wherein the cell is a eukaryotic cell. 21 . The method of claim 1 wherein the cell is a yeast cell, a plant cell or an animal cell. 22 . The method of claim 1 wherein the cell is a somatic cell. 23 . The method of claim 1 wherein the cell is a stem cell. 24 . The method of claim 1 wherein the cell is a human stem cell. 25 . The method of claim 1 comprising introducing into the cell a first foreign nucleic acid encoding the TALEN, wherein the TALEN is expressed, and wherein the TALEN cleaves the target DNA to produce altered DNA in the cell. 26 . The method of claim 1 comprising introducing into the cell a virus including a first foreign nucleic acid encoding the TALEN, wherein the TALEN is expressed, and wherein the TALEN cleaves the target DNA to produce altered DNA in the cell. 27 . The method of claim 1 comprising introducing into the cell a first foreign nucleic acid encoding the TALEN having a TALE sequence (SEQ ID NO: 24) CTAACCCCTGAACAGGTAGTCGCTATAGCTTCAAATATCGGGGGCAAGC AAGCACTTGAGACCGTTCAACGACTCCTGCCAGTGCTCTGCCAAGCCCA TGGATTGACTCCGGAGCAAGTCGTCGCGATCGCGAGCAACGGCGGGGGG AAGCAGGCGCTGGAAACTGTTCAGAGACTGCTGCCTGTACTTTGTCAGG CGCATGGTCTCACCCCCGAACAGGTTGTCGCAATAGCAAGTAATATAGG CGGTAAGCAAGCCCTAGAGACTGTGCAACGCCTGCTCCCCGTGCTGTGT CAGGCTCACGGTCTGACACCTGAACAAGTTGTCGCGATAGCCAGTCACG ACGGGGGAAAACAAGCTCTAGAAACGGTTCAAAGGTTGTTGCCCGTTCT GTGCCAAGCACATGGGTTAACACCCGAACAAGTAGTAGCGATAGCGTCA AATAACGGGGGTAAACAGGCTTTGGAGACGGTACAGCGGTTATTGCCGG TCCTCTGCCAGGCCCACGGACTTACGCCAGAACAGGTGGTTGCAATTGC CTCCAACATCGGCGGGAAACAAGCGTTGGAAACTGTGCAGAGACTCCTT CCTGTTTTGTGTCAAGCCCACGGCTTGACGCCTGAGCAGGTTGTGGCCA TCGCTAGCCACGACGGAGGGAAGCAGGCTCTTGAAACCGTACAGCGACT TCTCCCAGTTTTGTGCCAAGCTCACGGGCTAACCCCCGAGCAAGTAGTT GCCATAGCAAGCAACGGAGGAGGAAAACAGGCATTAGAAACAGTTCAGC GCTTGCTCCCGGTACTCTGTCAGGCACACGGTCTAACTCCGGAACAGGT CGTAGCCATTGCTTCCCATGATGGCGGCAAACAGGCGCTAGAGACAGTC CAGAGGCTCTTGCCTGTGTTATGCCAGGCACATGGCCTCACCCCGGAGC AGGTCGTTGCCATCGCCAGTAATATCGGCGGAAAGCAAGCTCTCGAAAC AGTACAACGGCTGTTGCCAGTCCTATGTCAAGCTCATGGACTGACGCCC GAGCAGGTAGTGGCAATCGCATCTCACGATGGAGGTAAACAAGCACTCG AGACTGTCCAAAGATTGTTACCCGTACTATGCCAAGCGCATGGTTTAAC CCCAGAGCAAGTTGTGGCTATTGCATCTAACGGCGGTGGCAAACAAGCC TTGGAGACAGTGCAACGATTACTGCCTGTCTTATGTCAGGCCCATGGCC TTACTCCTGAGCAAGTCGTAGCTATCGCCAGCAACATAGGTGGGAAACA GGCCCTGGAAACCGTACAACGTCTCCTCCCAGTACTTTGTCAAGCACAC GGGTTGACACCGGAACAAGTGGTGGCGATTGCGTCCAACGGCGGAGGCA AGCAGGCACTGGAGACCGTCCAACGGCTTCTTCCGGTTCTTTGCCAGGC TCATGGGCTCACGCCAGAGCAGGTGGTAGCAATAGCGTCGAACATCGGT GGTAAGCAAGCGCTTGAAACGGTCCAGCGTCTTCTGCCGGTGTTGTGCC AGGCGCACGGACTCACACCAGAACAAGTGGTTGCTATTGCTAGTAACAA CGGTGGAAAGCAGGCCCTCGAGACGGTGCAGAGGTTACTTCCCGTCCTC TGTCAAGCGCACGGCCTCACTCCAGAGCAAGTGGTTGCGATCGCTTCAA ACAATGGTGGAAGACCTGCCCTGGAA, or a sequence having at least 90% sequence identity to the TALE sequence, wherein the TALEN is expressed, and wherein the TALEN cleaves the target DNA to produce altered DNA in the cell. 28 . The method of claim 1 comprising introducing into the cell a virus including a first foreign nucleic acid encoding the TALEN having a TALE sequence

Assignees

Inventors

Classifications

  • C12N2830/003

    tet inducible · CPC title

  • C12N2800/90

    Vectors containing a transposable element · CPC title

  • C07H21/02

    with ribosyl as saccharide radical · CPC title

  • C12N5/0696

    Artificially induced pluripotent stem cells, e.g. iPS · CPC title

  • C12N15/85Primary

    for animal cells · CPC title

Patent family

Related publications grouped by family.

View patent family 52390824

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016369301A1 cover?
Methods of genome engineering in cells using a TALEN lacking repeat sequences or Cas9 is provided.
Who is the assignee on this patent?
Harvard College
What technology area does this patent fall under?
Primary CPC classification C12N15/85. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Dec 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).